366 related articles for article (PubMed ID: 28725983)
1. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
3. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
[TBL] [Abstract][Full Text] [Related]
4. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
[TBL] [Abstract][Full Text] [Related]
6. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
8. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
[TBL] [Abstract][Full Text] [Related]
9. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
10. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.
Giner-Soriano M; Roso-Llorach A; Vedia Urgell C; Castells X; Capellà D; Ferreira-González I; Elorza-Ricart JM; Casajuana M; Troncoso Mariño A; Diògene E; Bolíbar B; Violan C; Morros R
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):97-107. PubMed ID: 27868275
[TBL] [Abstract][Full Text] [Related]
12. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
14. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
[TBL] [Abstract][Full Text] [Related]
15. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B
High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
van Hulst M; Stevanovic J; Jacobs MS; Tieleman RG; Kappelhoff B; Postma MJ
J Med Econ; 2018 Jan; 21(1):38-46. PubMed ID: 28836865
[TBL] [Abstract][Full Text] [Related]
17. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.
Reers S; Agdirlioglu T; Kellner M; Borowski M; Thiele H; Waltenberger J; Reppel M
Eur J Med Res; 2016 Oct; 21(1):41. PubMed ID: 27769294
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Carmo J; Moscoso Costa F; Ferreira J; Mendes M
Thromb Haemost; 2016 Sep; 116(4):754-63. PubMed ID: 27465747
[TBL] [Abstract][Full Text] [Related]
19. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
